Tahoe Therapeutics
PrivateLast Round
Series A
Aug 11, 2025
Est. Valuation
$120M
Total Funding Raised
$42.25M
Company Overview
Tahoe Therapeutics operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series A round in August 2025.
Tahoe Therapeutics is a biotechnology company that develops AI-powered models of the human cell to facilitate the design of better drugs for patients, with an initial focus on cancer.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Synthetic Data, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Foundation
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tahoe Therapeutics Comparables
Compare Tahoe Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Transcripta Bio | 82% | |
| Gordian Biotechnology | 82% | |
| Noetik | 80% |
For institutional investors. Book with your work email.
Tahoe Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 11, 2025 | ||||
| Seed | Dec 8, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Tahoe Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Camford Capital | Seed |
| Conviction | Series A |
| General Catalyst | Series A, Seed |
| Mubadala Capital | Series A, Seed |
| Wing Venture Capital | Series A, Seed |
| Amplify Partners | Series A |
| Camford Capital | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
Announced Tahoe-x1 for rapid ML model iteration.
- Jan 1, 2026
Launched Tahoe-100M, a large-scale single-cell dataset for training foundation models.
For institutional investors. Book with your work email.
Tahoe Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tahoe Therapeutics's valuation, stock price, and market status.
Is Tahoe Therapeutics a public or private company?
Tahoe Therapeutics is a private company.
What is the current stock price of Tahoe Therapeutics?
Tahoe Therapeutics is a private company, so its shares have no public market price. Caplight tracks Tahoe Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tahoe Therapeutics worth (valuation)?
Tahoe Therapeutics's valuation is estimated at $120.0M based on funding round data.
Can I buy Tahoe Therapeutics stock?
Tahoe Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tahoe Therapeutics's last funding round?
Tahoe Therapeutics's most recent funding round was Series A on August 11, 2025.
Who are the main investors in Tahoe Therapeutics?
Key investors in Tahoe Therapeutics include General Catalyst, Wing Venture Capital, Amplify Partners.
Will Tahoe Therapeutics IPO soon?
No public IPO plans have been announced for Tahoe Therapeutics.
How can I track Tahoe Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Tahoe Therapeutics's shares on secondary markets.